Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines
- 1 June 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (6), 1854-1860
- https://doi.org/10.1097/00003246-200006000-00028
Abstract
To determine the time course of big-endothelin (big-ET) and its relationship to proinflammatory cytokines and organ function in sepsis. Prospective analysis in patients meeting criteria of severe sepsis as part of a multicenter study (RAMSES) with an anti-tumor necrosis factor monoclonal antibody F(ab')2 fragment (afelimomab). University hospital intensive care unit. A total of 23 nontrauma patients with severe sepsis or septic shock and ten multiple trauma patients. Septic patients were randomized for additional experimental treatment when initial interleukin (IL)-6 serum level was above 1000 pg/mL. Randomized patients received 1.0 mg/kg afelimomab or placebo three times daily over 3 days in addition to standard treatment. In each patient, serial blood samples for plasma big-ET and cytokine determination as well as clinical data were collected over 28 days. Significantly increased concentrations of circulating big-ET were found in patients with severe sepsis as compared with healthy subjects. In septic patients, big-ET plasma levels were higher than in multiple trauma patients, and were more elevated in randomized than in nonrandomized patients. At study entry (day 0), big-ET reached a peak concentration and significantly correlated with IL-6 (r2 = .43) and IL-8 (r2 = .44) in patients with severe sepsis. Moreover, big-ET levels in septic patients, pooled over all observation days, correlated positively with pressure-adjusted heart rate, central venous pressure, pulmonary artery pressure, and pulmonary vascular resistance and correlated inversely with creatinine clearance (r2 = .54, .54, .59, .40, and .51, respectively, p = .0001). In all randomized septic patients, pressure-adjusted heart rate decreased from day 0 to day 2 in parallel with big-ET; however, a significant decrease in big-ET (day 0 to day 2) was only found in patients additionally treated with afelimomab. In patients with severe sepsis, big-ET plasma levels are markedly increased, even above those of multiple trauma patients, in close relationship to IL-6 and IL-8, and with significant correlation to renal function and pulmonary vascular tone.Keywords
This publication has 32 references indexed in Scilit:
- Molecular pharmacology of endothelin converting enzymesBiochemical Pharmacology, 1996
- Radioimmunoassay evidence that the pressor effect of big endothelindash1 is due to local conversion to endothelindash1Biochemical Pharmacology, 1995
- Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currentsNature, 1994
- Growth regulatory properties of endothelinsPeptides, 1993
- Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor.Proceedings of the National Academy of Sciences, 1991
- Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro.Proceedings of the National Academy of Sciences, 1991
- Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbitBiochemical Pharmacology, 1990
- Conversion of Big Endothelin-1 to 21-Residue Endothelin-1 Is Essential for Expression of Full Vasoconstrictor ActivityJournal of Cardiovascular Pharmacology, 1989
- Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.Proceedings of the National Academy of Sciences, 1988
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988